Drugs / efavirenz/emtricitabine/tenofovir disoproxil fumarate
efavirenz/emtricitabine/tenofovir disoproxil fumarate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01352117 Background | Nov 2011 → Mar 2016 | HIV infectious disease, Kaposi's sarcoma | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | efavirenz/emtricitabine/tenofovir disoproxil fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01352117 ↗ |
| Route | Oral | “taken orally at night” NCT01352117 ↗ |